• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mallinckrodt - Articles and news items


Mallinckrodt’s muscular dystrophy drug receives FDA fast track designation

Industry news / 26 August 2016 / Niamh Louise Marriott, Digital Content Producer

For the treatment of Duchenne muscular dystrophy (DMD), Synacthen Depot is a synthetic 24 amino acid melanocortin receptor agonist. Outside the US, it…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +